News Related to University of Cambridge

Related coverage linked through entity extraction aliases.

Nucleome Therapeutics Appoints Dr. Michelle Morrow as Chief Scientific Officer

Feb 16, 2026

Nucleome Therapeutics announces Dr. Michelle Morrow as CSO effective February 23, 2026, bringing two decades of drug discovery experience as the company advances lead candidate NTP464 toward IND enabling studies.

Roche's Gazyva Meets Primary Endpoint in Phase III Trial for Primary Membranous Nephropathy

Feb 16, 2026

Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.